Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821). On January 8, 2025, ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...

Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

My tailored session combined life coaching, hypnotherapy, meditation, breathwork, vision-crafting skills and strategic ...

ARC-EX is the first and only FDA approved technology indicated to improve hand strength and sensation in people with spinal cord injury ...